NEUROGEN CORP 274 62 336 40 Tyler Dylan CARDIUM THERAPEUTICS INC 335 0 335 41 Michael S. Rabson Ph.D CYTOKINETICS INC 331 0 331 42 Chen Schor EPIX PHARMACUETICALS INC 262 66 327 43 Jeffrey P. Brennan TARGACEPT INC 277 50 326 44 John Randle COMBINATORX INC 283 42 326 45 Michael J. Dwyer ZYMOGENETICS INC 294 29 323 46 Christopher J. Margolin XOMA LTD 322 0 322 47 Eric H. Bjerkholt SUNESIS PHARMACEUTICALS INC 321 0 321 48 Frank Bobe Ph.D., M.B.A

Michael J. Dwyer 294 29 323 16 585 924 0 0

The top paid COO was Michael J. Walsh, of Cypress Bioscience Inc., of San Diego, who earned cash compensation totaling $2 million in 2008, most of that – about $1.7 million – in bonus payments

Semprus BioSciences Inc, of Cambridge, Mass., appointed Colin R. Gardner and Michael J. Cima to its scientific advisory board

Company* (Country; Symbol)University/Nonprofit@Type Of AgreementProduct AreaDetails (Date) FOURTH QUARTER Agios Pharmaceutical*Accelerate Brain Cancer Cure Agreement For new research investigating IDH1 gene mutations in brain cancer Funding will supplement Agios' ongoing research into the development of new IDH1 therapeutics and diagnostics (12/21) Alethia Biotherapeutics Inc.* (Canada) Canada's National Research Council Biotechnology Research Institute Licensing agreement For exclusive

Company* (Country; Symbol)Funding InstitutionAmount (US$M)TypeDetails (Date) THIRD QUARTER 2009 ActoGeniX NV* (Belgium) Flemish government €0.9 ($1.3) Grant To support the development of AG013, for the treatment of oral mucositis in cancer patients (8/20) Adolor Corp. (ADLR), Amylin Pharmaceuticals Inc. (AMLN), Isis Pharmaceuticals Inc. (ISIS), Targacept Inc. (TRGT), Neurodyne Inc.*, reMYND NV* and Sign Path Pharma Inc.* Michael J. Fox Foundation for Parkinson's Research $3.8 Grants For

Addex Pharmaceuticals Inc., of Geneva, said ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. ADX71943 is an orally available positive allosteric modulator of the GABA(B) receptor that has potential for treatment of osteoarthritis pain and chronic nociceptive pain as well as other indications. ADX71943 has a good developability profile and is expected to enter clinical testing in the fourth quarter, according to the company

The Michael J. Fox Foundation for Parkinson's Research in New York awarded a total of $2.1 million to six biotech and pharmaceutical companies to drive preclinical projects focused on neuroprotective therapeutic targets for Parkinson's disease

NeurAxon Inc., of Waltham, Mass., received a $267,000 grant from the Michael J. Fox Foundation for Parkinson's Research to fund research exploring neuronal nitric oxide synthase (nNOS) inhibitors as a potential treatment paradigm in Parkinson's disease

Dyadic International Inc., of Jupiter, Fla., named Michael J. Faby vice president of finance, effective Jan. 4, 2010

Aeolus Pharmaceuticals Inc., of Mission Viejo, Calif., said the University of Colorado Denver's School of Pharmacy received a grant from the Michael J. Fox Foundation for optimization of a series of metalloporphyrins such as AEOL 11207 in Parkinson's disease

That prompted a re-think, and with the help of $1.16 million grant funding from the Michael J Fox Foundation, Cogane has advanced to the point where investors can be lured in

That prompted a re-think, and with the help of $1.16 million grant funding from the Michael J Fox Foundation, Cogane has advanced to the point where investors can be lured in

NeurAxon Inc., of Toronto, and Chaperone Therapeutics Inc., of Durham, N.C., were among the six companies and academic institutions awarded portions of a $1.5 million grant from the Michael J. Fox Foundation for Parkinson's Research to develop disease-modifying therapies for Parkinson's disease

Company* (Country; Symbol)University/Nonprofit@Type Of AgreementProduct AreaDetails (Date) SECOND QUARTER (MAY 1 - JUNE 30) Advanced Cancer Therapeutics*University of Louisville Exclusive license To develop and commercialize small molecule compound inhibitors of choline kinase, an enzyme required for the survival of tumors Financial details were not disclosed (6/3) Aeolus Pharmaceuticals Inc. (OTC BB:AOLS) National Institute of Allergy and Infectious Diseases Development agreement To

Sigma-Aldrich Co., of St. Louis, said it is collaborating with the Michael J. Fox Foundation to develop more accurate preclinical research models of Parkinson's disease

Ceregene Inc., of San Diego, said the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase II trial of CERE-120 for Parkinson's disease

Michael J. Fox Foundation for Parkinson's Research $3.8 Grants For preclinical Parkinson's drug development projects (7/21) Affectis Pharmaceuticals AG* (Germany) Bavarian Ministry of Economics €0.55 ($0.77) Bavarian Technology Promotion Program grant To fund the identification and characterization of drug candidates to treat major depression (7/9) America Stem Cell Inc.*Texas Emerging Technology Fund $2.5 Grant To accelerate the development of its enzyme technology for the homing and

Targacept Inc., of Winston-Salem, N.C., was awarded a grant of more than $600,000 from the Michael J. Fox Foundation for Parkinson's Research